1
/
of
0
Plerifor (Plerixafor)
Plerifor (Plerixafor)
Regular price
₱144,000.00 PHP
Regular price
Sale price
₱144,000.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Plerifor (Plerixafor) is an injectable prescription medication used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells from the bone marrow into the bloodstream. This mobilization enables effective stem cell collection and harvesting for autologous stem cell transplantation in patients with blood cancers.
Plerixafor works as a CXCR4 chemokine receptor antagonist, blocking the receptor that anchors stem cells to bone marrow tissue. By inhibiting this anchor mechanism, the medication allows CD34+ stem cells to flood into the peripheral blood circulation, where they can be efficiently collected through apheresis during medical procedures.
This medication is primarily indicated for patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) who require stem cell transplantation. The drug is specifically designed to improve stem cell mobilization rates, particularly in patients who may have suboptimal mobilization responses to G-CSF alone.
Important considerations include contraindications for patients with hypersensitivity to plerixafor. Caution is advised in patients with active leukemia due to the theoretical risk of mobilizing malignant cells, those with renal impairment requiring dose adjustment, and individuals with splenic enlargement due to rare splenic rupture risks.
Dosage must be determined by your healthcare provider based on individual patient factors and clinical requirements. This is a prescription-only medication requiring direct medical supervision and should never be used without proper consultation and guidance from a qualified healthcare professional. Always follow your physician's specific instructions regarding administration and monitoring while taking this medication.
Plerixafor works as a CXCR4 chemokine receptor antagonist, blocking the receptor that anchors stem cells to bone marrow tissue. By inhibiting this anchor mechanism, the medication allows CD34+ stem cells to flood into the peripheral blood circulation, where they can be efficiently collected through apheresis during medical procedures.
This medication is primarily indicated for patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) who require stem cell transplantation. The drug is specifically designed to improve stem cell mobilization rates, particularly in patients who may have suboptimal mobilization responses to G-CSF alone.
Important considerations include contraindications for patients with hypersensitivity to plerixafor. Caution is advised in patients with active leukemia due to the theoretical risk of mobilizing malignant cells, those with renal impairment requiring dose adjustment, and individuals with splenic enlargement due to rare splenic rupture risks.
Dosage must be determined by your healthcare provider based on individual patient factors and clinical requirements. This is a prescription-only medication requiring direct medical supervision and should never be used without proper consultation and guidance from a qualified healthcare professional. Always follow your physician's specific instructions regarding administration and monitoring while taking this medication.